Multiparameter modalities for the study of patients in the setting of individualized medicine

Miyabayashi, K., Tuveson, D. A., Yu, K. H. (2018) Multiparameter modalities for the study of patients in the setting of individualized medicine. In: Pancreatic Cancer. Springer Nature, pp. 1523-1549. ISBN 9781493971930 (ISBN); 9781493971916 (ISBN)

DOI: 10.1007/978-1-4939-7193-0_65


The recent revolution in cancer genetics offers the promise of using genetic information to individualize patient treatment. In pancreatic cancer, numerous studies have described a genetic landscape characterized by a set of commonly mutated genes aggregated into core molecular pathways accompanied by numerous but infrequently mutated genes. Studies have also demonstrated significant intratumoral heterogeneity. Resistance against chemotherapeutic agents has also been attributed to difficulty of drug delivery through a rich stromal microenvironment. For these reasons, therapeutic development against pancreatic cancer has been challenging, and a number of promising agents have failed clinical trial testing. Personalized models have been studied as a tool for testing candidate drugs to select the most efficacious treatment. The patient-derived xenograft (PDX) is a well-established preclinical tool to improve the drug screening and development. The PDX model requires adequate tissue for transplantation, and failure is common. A recently described, innovative three-dimensional organoid culture platform can be exploited for genomic and functional studies at the level of the individual patient for personalized treatment approach. Organoid technology may fill the gap between cancer genetics and patient trials and allow personalized therapy design. Combination of genome-based medicine and individualized model-based drug screening may fulfill the promise of precision medicine for pancreatic cancer. © Springer Science+Business Media, LLC, part of Springer Nature 2018.

Item Type: Book Section
Subjects: Investigative techniques and equipment > cell culture > cancer organoids
diseases & disorders > cancer > cancer types > pancreatic cancer
CSHL Authors:
Communities: CSHL labs > Tuveson lab
Depositing User: Matthew Dunn
Date: 2018
Date Deposited: 12 Nov 2018 21:12
Last Modified: 12 Nov 2018 21:12

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving